Business Context and Reporting Period
This Form 6-K filing covers the month of November 2017 for Prana Biotechnology Limited, a development stage enterprise based in Australia. The filing reports on the execution of Amendment No. 1 to an At Market Issuance Sales Agreement entered into on November 8, 2017. Note: The request metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on capital market activities. Key figures related to the financing arrangement include:
- Aggregate Offering Size: Up to $44,460,787 of ordinary shares (represented by American Depositary Shares).
- Commission Rate: Agents are entitled to a fixed commission of up to 3.0% of the gross sales price per share sold.
- Previous Prospectus Supplement: Relates to an offering of up to $10,019,412 in ADSs filed on November 8, 2016.
Material Changes
The primary material change reported is the amendment of the existing Sales Agreement dated October 13, 2016. This amendment, executed on November 8, 2017, involves the same agents (B. Riley FBR, Inc. and JonesTrading Institutional Services LLC) and maintains the framework for an "at the market offering" program. The filing incorporates the amended agreement by reference.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding operational guidance, future outlook, or specific risk factors beyond standard securities law disclaimers. The document notes that sales of ADSs may be made by any method permitted by law deemed to be an "at the market offering" under Rule 415. It explicitly states that the report does not constitute an offer to sell or a solicitation of an offer to buy in any jurisdiction where such activity would be unlawful.
Investor Verification Checklist
- Verify the correct registrant name (Prana Biotechnology Limited) against the metadata provided (Alterity Therapeutics Ltd).
- Review the full text of Amendment No. 1 to the Sales Agreement (Exhibit 1.2) for specific terms not detailed in the summary.
- Confirm the current status of the $44,460,787 offering program and any shares sold to date under the amended agreement.
- Check subsequent filings for actual proceeds generated and the impact on the company's cash position.